• Explore /
  • Poster
  • / Phase I trial to determine safety and immunogenicity of amplivant, a synthetic toll-like receptor 2 ligand, conjugated to two HPV16 E6 synthetic long peptides.

Phase I trial to determine safety and immunogenicity of amplivant, a synthetic toll-like receptor 2 ligand, conjugated to two HPV16 E6 synthetic long peptides.

Abstract Poster

Authors

null

Frank M. Speetjens

Leiden University Medical Center, Department of Medical Oncology, Leiden, Netherlands

Frank M. Speetjens , Marij JP Welters , Marije Slingerland , Peggy de Vos van Steenwijk , Inge C.F.M. Roozen , Sanne Boekestijn , Nikki Loof , Gijs G Zom , Rob Valentijn , Willem-Jan Krebber , Cornelis JM Melief , Dmitri V Filippov , Hans Gelderblom , Sjoerd H van der Burg , Ferry Ossendorp

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Vaccines

Clinical Trial Registration Number

NCT02821494

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 2614)

DOI

10.1200/JCO.2021.39.15_suppl.2614

Abstract #

2614

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Johanna C. Bendell

First Author: Marije Slingerland

First Author: Craig L. Slingluff Jr.

First Author: Mary L. Disis